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Background: Feeding is a significant challenge for premature infants in the neonatal intensive care unit (NICU).
These patients are often treated with glycerin suppositories to stimulate the passage of meconium and prevent
feeding intolerance. Unfortunately, the evidence for this practice is inconclusive.
Methods/design: This protocol is for an external pilot study that will assess the feasibility of a superiority,
placebo-controlled, parallel-design, multicenter randomized controlled trial. Participants are premature infants
treated in a level 3 NICU with a gestational age 24 to 32 weeks and/or birth weight of 500 to 1500 g. Thirty
participants will be recruited as part of this external pilot study. Participants will be randomized to glycerin
suppository (250 mg) or placebo starting 48 to 72 h after birth and continuing once daily until meconium
evacuation is complete or for a maximum of 12 days. The placebo consists of a 250-mg glycerin suppository
placed in the diaper rather than the rectum. Study treatments are administered by the charge nurse on duty who is
not otherwise involved in patient care. All other clinicians and research personnel will remain blinded. Outcomes
for the pilot study are percentage of eligible participants randomized, percentage of infants reaching full enteral
feeds, cost, and treatment-related adverse events (rectal bleeding, rectal perforation, and anal fissure).
Discussion: This external pilot study will assess the feasibility of a multicenter randomized controlled trial of
glycerin suppositories in premature infants. The subsequent multicenter trial will have sufficient power to determine
whether this treatment strategy is associated with decreased time to full enteral feeds.
Trial registration: ClinicalTrials.gov: NCT02153606
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Feeding is a significant challenge for premature infants
in the neonatal intensive care unit (NICU) [1, 2]. These
babies have immature digestive tracts and can develop a
life-threatening bowel infection called necrotizing entero-
colitis (NEC) [3, 4]. Treatment of this condition may re-
quire surgery and is associated with substantial morbidity* Correspondence: livingm@mcmaster.ca
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this article, unless otherwise stated.and mortality. This includes short bowel syndrome,
dependence on parenteral nutrition, and/or need for
additional surgery [5, 6].
Infants who do not develop NEC can still have issues
with feeding and growth. Most are supported with intra-
venous nutrition while enteral feeds are advanced over a
period of 1 to 3 weeks. This process can be delayed if
infants develop feeding intolerance, characterized by
abdominal distension, undigested feeds in the stomach,
and decreased bowel movements [7]. This can lead to
increased reliance on intravenous nutrition, which is
associated with sepsis, extrauterine growth restriction,
and poor neurodevelopmental outcomes [1, 2, 8].rticle is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
ense, and indicate if changes were made. The Creative Commons Public
ommons.org/publicdomain/zero/1.0/) applies to the data made available in
Table 1 Participant inclusion and exclusion criteria
Criteria Definition
Inclusion (any of the following)
Gestational age 24–32 weeks gestation
Birth weight 500–1500 g










Suspected coagulopathy Bleeding from any orifice
Confirmed coagulopathy International normalized ratio >1.4
Partial thromboplastin time >39 s
Fibrinogen <1.00 g/L
Platelet count <100 × 109/L
Neutropenia Absolute neutrophil count <0.5 × 109/L
Complete meconium
evacuation
2 bowel movements with no
meconium
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ture infants to stimulate the passage of meconium and
improve feeding tolerance [9]. This practice is based on
the observation that preterm infants experience signifi-
cant delays in the passage of meconium, which is more
viscous than normal stool [10, 11]. Delays in meconium
evacuation appear to be associated with a delay in the
transition to enteral feeding [12]. Thus, if meconium
evacuation could be expedited through the use of gly-
cerin suppositories, this may lead to faster transition to
enteral feeding, decreased reliance on intravenous nutri-
tion, and better outcomes. Unfortunately, there is little
evidence to support this practice [9–17].
We recently conducted a systematic review on the use
of glycerin suppositories and enemas in premature infants
[17]. We identified a total of 185 infants from three single-
center, randomized controlled trials [14–16]. These studies
focused on the prophylactic use of glycerin suppositories
(two trials) or enemas (one trial). Across all three trials,
there were no differences in terms of meconium evacu-
ation, transition to full enteral feeding, or mortality. There
were no reports of rectal bleeding or perforation, but
meta-analyzed data revealed a non-significant trend to-
wards increased risk of NEC with active treatment. We
concluded that going trials should be carefully monitored
and stopped if it becomes clear that this trend is a real
effect and not just a spurious correlation.
The results of our systematic review were complicated
by the fact that all three trials were underpowered and
affected by one or more major methodological issues. As
a result, the quality of evidence was low to very low. We
concluded that the evidence for the use of glycerin sup-
positories or enemas in premature infants is inconclusive
and that further research is required. As a result, we
designed an external pilot study to assess the feasibility
of a multicenter randomized controlled trial of prophy-
lactic glycerin suppositories in premature infants.
Methods/design
Study design and objective
The glycerin suppositories used prophylactically in pre-
mature infants (SUPP) trial is an external pilot study for
a superiority, placebo-controlled, parallel-design, multi-
center randomized controlled trial [18]. The purpose of
the multicenter trial is to determine whether glycerin
suppositories decrease the time to full enteral feeding in
premature infants. We hypothesize that the multicenter
trial will demonstrate that using glycerin suppositories
in premature infants results in earlier completion of
meconium evacuation. Whether this treatment strategy
results in earlier full enteral feeding or improvements in
other outcomes remains unclear [17].
The study protocol described here is for an external
pilot study to assess the feasibility of a multicenterrandomized controlled trial [19, 20]. This includes as-
sessments of cost, recruitment, protocol violations, post-
randomization exclusions, and treatment-related adverse
events. The pilot will also allow us to determine if modifi-
cations to the inclusion or exclusions criteria or duration
of study treatments might be required in the multi-
center trial.Setting
Premature infants will be recruited from the level 3
NICU at McMaster Children’s Hospital in Hamilton,
Ontario, Canada. This unit treats almost 1000 infants
per year of which approximately 150 would be eligible
for our trial.Participants
The participants will be premature infants 24 to 32 weeks
and/or birth weight 500 to 1500 g (Table 1). Exclusion
criteria include the following: congenital gastrointestinal
anomalies, surgery within 48 h of birth; culture-proven
sepsis, vasopressors, nitric oxide, prostaglandins, suspec-
ted coagulopathy (bleeding from any orifice), confirmed
coagulopathy (international normalized ratio >1.4, partial
thromboplastin time >39 s, fibrinogen <1.00 g/L, platelet
count <100 × 109/L), neutropenia (absolute neutrophil
count <0.5 × 109/L), and complete meconium evacuation
within 48 h after birth.
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Participants randomized to active treatment will receive
a 250-mg glycerin suppository once daily starting 48 to
72 hours after birth (i.e., on day 3 of life). This smaller
suppository will be created by cutting the tip off of a
1440 mg glycerin suppository. In order to maintain con-
sistent dosing, we created a plastic measurement guide
that results in a 250-mg suppository (Fig. 1). This “tip”
will be covered with a water-based lubricant and placed
in the infant’s rectum.
Participants in the control group will receive placebo
suppositories. In usual practice, partially dissolved sup-
positories are often ejected from the rectum either with or
without stool. In our trial, leaving a suppository in the
diaper (but not in the rectum) makes it ambiguous as to
whether it was placed in the rectum and ejected or simply
placed in the diaper. This approach also ensures that treat-
ment will appear to have been administered to all infants,
even if they happen to be in the control group.
Following administration of either treatment, the glu-
teal buttocks will be held together for 30 s to minimize
the likelihood of the suppository being ejected from the
rectum. Participants in the each treatment group will re-
ceive study treatments once daily until they pass two
normal bowel movements free of meconium staining. A
similar duration of treatment was used in the random-
ized controlled trial of glycerin enemas from Austria
[14]. Maximum treatment duration will be 12 days (i.e.,
all treatments will stop on day 14 of life).
All study interventions will be administered by one of
the NICU charge nurses on duty. These individuals have
years of experience working in the NICU but are not in-
volved in the care of individual patients. All participants
will receive a medical order of “nil per rectum” during
the period of study treatments. This will be removed once
study treatments stop. Study participants will be eligibleFig. 1 Plastic measurement guide to ensure consistent dose of
glycerin suppositoriesfor rescue glycerin suppository therapy if they are judged
by the medical team to have feeding intolerance.
Randomization
Infants will be allocated to treatment groups via web-
based stratified blocked randomization. Previous studies
have shown that the size of the infant is highly predictive
of the time to full enteral feeds [13]. In order to main-
tain prognostic balance, participants will be stratified by
gestational age: (1) 24–27 weeks 6 days; or (2) 28–31
weeks 6 days. This strategy has been used in other
randomized controlled trials of feeding intolerance in
premature infants [14, 15, 21, 22]. See Fig. 2 for an over-
view of the external pilot study.
Sequence generation will be created using random num-
ber software by an unblinded research assistant not other-
wise involved in the SUPP Trial. Block size will range
from four to six to ensure that there are an equal number
of participants in the treatment and control groups.
Randomization of study participants will be completed
online by a blinded research assistant immediately prior to
the administration of the first study treatment. This web-
based system will be created using Research Electronic
Data Capture (REDCap) software [23]. For each partici-
pant, REDCap will assign a three-digit treatment code that
will be recorded by the blinded research assistant on the
infant’s bedside chart. The charge nurse will use a coding
sheet to link the three-digit number for each participant
with either active treatment or placebo.
Blinding
The principal investigator, co-investigators, parents or
guardians, physicians, bedside nurses, allied health profes-
sionals (e.g., dieticians), research assistants, outcome asses-
sors, and statistical analysts will be blinded to treatment
allocation. The only groups who will be unblinded are the
participants (i.e., the premature infants who cannot com-
municate) and the charge nurses responsible for adminis-
tering study treatments. Adequate blinding of medical staff,
bedside nurses, and allied health professionals is essential
since these clinicians typically make decisions about advan-
cing or holding feeds during daily patient rounds. If these
individuals are aware which treatment the participant is re-
ceiving, there is a chance that this knowledge will affect
their decision-making and bias the results.
We will employ several strategies to maintain blinding.
First, participants in the control group will receive sup-
positories placed in the diaper rather than no interven-
tion at all. Second, all study treatments will be
administered when the participant’s crib is covered. This
will ensure that only the charge nurse administering the
treatment knows which intervention is given. Third, we
have held multiple meetings with the NICU nursing staff
prior to the start of the trial to discuss the purpose of
Assessed for eligibility
Gestational age 24-32 weeks








1. Percentage of eligible infants randomized
2. Percentage of infants reaching full enteral feeds
3. Cost
4. Treatment-related adverse events
Assess outcomes if infant:
Reaches 40 weeks gestational age
Transferred to another hospital
Dies
Assess outcomes if infant:
Reaches 40 weeks gestational age
Transferred to another hospital
Dies
Glycerin suppository (250 mg) in diaper
Start on day 3 of life (48 to 72 hours)
Administer once daily
Hold one day for coagulopathy or neutropenia
Stop after complete meconium evacuation
Maximum treatment duration = 12 days
1. Percentage of eligible infants randomized
2. Percentage of infants reaching full enteral feeds
3. Cost
4. Treatment-related adverse events
Stratified (24-28 or 28-32 weeks gestation) and Randomized
Glycerin suppository (250 mg) in rectum
Start on day 3 of life (48 to 72 hours)
Administer once daily
Hold one day for coagulopathy or neutropenia
Stop after complete meconium evacuation
Maximum treatment duration = 12 days
Fig. 2 Overview of glycerin suppositories used prophylactically in premature infants (SUPP) trial
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these individuals.
Duration of treatment
Infants enrolled in this trial will receive active treatment or
placebo once daily until meconium evacuation is complete.
This will be defined as two bowel movements free of meco-
nium staining. Previous studies have demonstrated that this
process takes approximately 6 to 9 days [14]. The study
intervention will be withheld and reassessed daily in cases of
thrombocytopenia (platelet count < 100 × 109/L), suspected
coagulopathy (bleeding from any orifice, confirmed
coagulopathy (international normalized ratio >1.4, par-
tial thromboplastin time >39 s, fibrinogen <1.00 g/L,thrombocytopenia (platelet count <100 × 109/L), or neu-
tropenia (absolute neutrophil count <0.5×109/L).
The study intervention will be stopped early in cases of
clinical deterioration (vasopressors, prostaglandins, culture-
proven sepsis, NEC, or death) or treatment-related adverse
events (rectal bleeding, rectal perforation, or anal fissure).
Previous trials of glycerin suppositories and enemas did not
report single case of rectal bleeding, rectal perforation, or
anal fissure [14–16]. As such, the risk of these events occur-
ring in the current study is low.
Follow-up
Outcome data will be extracted from the medical record
after participants are discharged from hospital, reach a
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happens first). The research assistant will also assess par-
ticipants on at least a weekly basis to maintain contact
with nursing staff, discuss any protocol violations, moni-
tor for adverse events, and address any other issues that
arise. Nursing staff will also be instructed to submit pos-
sible adverse events to the research assistant as soon as
they occur. These include any cases of rectal bleeding,
rectal perforation, and anal fissure.
Outcomes
Outcomes for the external pilot study will be re-
cruitment rate (i.e., percentage of eligible infants ran-
domized), completion rate (i.e., percentage of infants
reaching the primary endpoint of full enteral feeds), and
treatment-related adverse events (i.e., safety outcomes).
The pilot study will also allow us to better estimate the
explicit cost per infant of conducting a randomized trial
on this topic (i.e., considering the total costs of database
design, data storage, printed materials, and salary for re-
search assistants). We will also assess the frequency and
type of protocol violations and post-randomization
exclusions.
The primary outcome for the multicenter trial will be
time in days to full enteral feeding (defined as 150 mL/
kg/day). Advancing the rate of enteral feeds is typically
based on a standardized NICU feeding protocol [24–26].
Deviations from this protocol occur when infants be-
come unwell, develop signs of feeding intolerance, or if
there are other clinical concerns. Secondary outcomes
will include feeding volume on day 14 of life (in mL/kg),
days to complete meconium evacuation, days of paren-
teral nutrition, incidence of NEC, incidence of line sep-
sis, compliance with treatment regimen, and mortality.
Sample size
For the external pilot study, we hope to recruit 30 par-
ticipants (15 per group) over a 6-month period. Previous
reviews recommend using at least 12 participants per
group, and some indicated that a total sample size of 30
may be more appropriate [27–29].
Potential pitfalls
Adherence to the study protocol was a serious issue in a
randomized controlled trial of glycerin enemas from
Austria [14]. This may have occurred because some cli-
nicians did not believe in the efficacy of glycerin enemas
and tended to withhold this intervention among partici-
pants in the therapeutic arm. This will be less of an issue
in our trial since glycerin suppositories are commonly
used in the NICU at McMaster Children’s Hospital and
are much less invasive.
Another issue to consider is post-randomization with-
drawals or exclusions. While this is an issue in anyrandomized controlled trial, this will present a unique
challenge in our study since participants will have been
alive for less than 48 h when they are enrolled. Some
infants may not have had prenatal screening and serious
congenital anomalies that would have excluded them
from the study may not be diagnosed until days or
weeks after randomization. Even in cases of excellent
prenatal care, some conditions (e.g., Hirschsprung’s
disease) cannot be diagnosed until the postnatal period
[30, 31]. The best way to handle this will be to follow all
randomized participants to the primary endpoint of
full enteral feeds and analyze the data on the basis of
intention-to-treat.
Losing participants to follow-up is unlikely to occur
since all premature infants are monitored in hospital
until they are tolerating full enteral feeds and reach
37 weeks corrected gestational age. Some participants
who are doing well clinically may be transferred to a
NICU in a community hospital that is not part of this
study, but this is unlikely to occur until after these in-
fants have reached full enteral feeds. Finally, the mortal-
ity rate in this population is approximately 10 % [32, 33].
While our exclusion criteria will exclude most of the in-
fants at risk for postnatal mortality, some participants
may die before they are randomized, complete the treat-
ment regimen, or reach full enteral feeds.
Statistical analysis
Frequencies and 95 % confidence intervals using normal
approximation will be used to estimate recruitment rate
and percentage infants reaching the primary endpoint.
We will also report the rate of protocol violations, post-
randomization exclusions, and incidence of adverse
events related to the study intervention. We will also
report the mean cost per infant randomized. All data
will be analyzed in the Statistics Package for the Social
Sciences (SPSS) [34].
Ethical and safety considerations
This study was approved by the Neonatal Research
Committee at McMaster Children’s Hospital, Hamilton
Integrated Research Ethics Board (14–575), and Health
Canada (9427-M1133-53C). All parents or guardians will
provide written and informed consent prior to enrollment.
We have established a Data Safety and Monitoring
Board (DSMB) for the pilot study, which consists of two
neonatologists and one pediatric surgeon. This group
will meet after the first five participants are randomized
and then once every 3 months until the pilot study is
complete. The DSMB will review safety outcomes (i.e.,
treatment-related adverse events) and can request un-
blinding should the need arise. Unblinding will be facili-
tated by the unblinded research assistant who performed
sequence generation and is not otherwise involved in
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gator, co-investigators, and research assistant will remain
blinded.
Discussion
The evidence for the use of glycerin suppositories in pre-
mature infants is inconclusive [9, 17]. In our recent sys-
tematic review, we considered the results from three
single-center randomized controlled trials of glycerin sup-
positories (two studies) or enemas (one study) [17]. The
trial focused on glycerin enemas included 81 very low
birth weight infants from a single hospital in Austria [14].
All participants were enrolled in the study shortly after
birth and stratified by gestational age either (1) 24–
27 weeks 6 days or (2) 28–31 weeks 6 days. Infants in the
intervention group received daily glycerin enemas if they
did not pass meconium spontaneously within 12 h of
birth. These enemas continued until complete evacuation
was achieved. The control group did not receive any
intervention.
This study was an open trial, the primary outcome
was the number of days to complete evacuation of
meconium, and the study was powered to detect a 30 %
difference. There was a trend towards a treatment effect
with complete evacuation of meconium occurring at a
median of 6.5 days in the intervention group and 9 days
in the control group, but this difference was not statisti-
cally significant (p = 0.11). No differences were reported
for any of the secondary outcomes, including duration
of hospital stay, weight at discharge, days to introduction
of oral feedings, feeding volume on day 14 of life, days
to passage of first meconium, or days to full enteral
feeding. This trial was limited by the lack of blinding,
possibility of selective reporting, small sample size, and
frequent protocol violations.
The second trial explored whether glycerin suppositor-
ies decrease feeding intolerance in premature infants
[15]. Participants were enrolled shortly after birth and
were randomized from a stack of opaque envelopes. This
study was an open trial, and there were no attempts to
maintain blinding. The primary outcome was days to full
enteral feeding. There was a trend towards a decrease in
time to full feeds of 1.6 days, but the study was only
powered to detect a difference of 3.6 days. There were
also no significant differences for any of the secondary
outcomes, including incidence of NEC, episodes of
culture-positive sepsis, feeding intolerance during the
first 10 days, growth and nutrition, and ventilation. Des-
pite this, infants in the intervention group passed their
first stool earlier (day 2) than controls (day 4) (p = 0.016)
and were less likely to pass their first stool after 48 h of
life (24 versus 64 %) (p = 0.003).
The third randomized controlled trial was published in
2014 [16]. This study included 50 premature infantsfrom a single hospital in India with a gestational age of
28 to 32 weeks and birth weight 1000 to 1500 g. Infants
less than 28 weeks gestation or 1000 g were excluded.
Participants randomized to active treatment received a
1000 mg glycerin suppository once daily starting on day
2 of life and continuing until day 14, regardless of stool-
ing pattern. Infants in the control group underwent a
placebo procedure, where the diaper was opened and
closed again, but no active treatment was administered.
All study treatments were administered by a research
nurse, and blinding was maintained for all other clinical
and research personnel.
This trial reported no differences between treatment
groups for any of the outcomes, including time to full
enteral feeds, time to regain birth weight, NEC, fre-
quency of feeds being withheld, and length of hospital
stay. The main limitations were small sample size, possi-
bility of selective reporting, and number of participants
lost to follow-up. In each group, 3/25 participants
(greater than 10 % of the total sample size) were trans-
ferred to another hospital before complete outcomes
could be obtained [16].
As shown above, previous trials on the use of glycerin
suppositories in premature infants are small, underpow-
ered, and affected by a variety of methodological issues
[17]. As such, the evidence for this treatment strategy is
inconclusive and clinical equipoise remains. The SUPP
trial will start as an external pilot study to assess feasibil-
ity. If minimal changes are required, we will develop a
similar protocol for a superiority, placebo-controlled,
parallel-design, multicenter randomized controlled trial.
Once completed, the multicenter trial will have sufficient
power to determine whether glycerin suppositories facili-
tate meconium evacuation and transition to enteral feed-
ing in premature infants.
Trial status
The SUPP trial started recruiting participants in January
2015 and is on track to complete enrollment of 30 par-
ticipants for the external pilot study by July 2015. An
update with results from the external pilot study will be
provided in 2016.
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